Advertisement PointCross offers SDIS technology to BioPharma industry - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

PointCross offers SDIS technology to BioPharma industry

PointCross has released its Study Data Integration and Search (SDIS) technology and associated services to the BioPharma industry for private use with legacy and current studies.

SDIS is a solution that closes a major gap in the nonclinical phase of the R&D lifecycle and also creates an instantly searchable resource of all nonclinical study and assay data for BioPharma companies and collaborative consortia like the C-PATH Predictive Safety Testing Consortium and the Innovative Medicines Initiative (IMI) in Europe.

PointCross Pharmaceuticals & Life Sciences VP Shree Nath said that imagine discovering two, 20 year old studies that exhibit similar behavior in certain sets of markers to a recent study and then discovering that the earlier drugs failed in the clinic due to toxicity.

"That would be like finding a gold mine while digging right in your own backyard using a new set of tools," Nath said.

PointCross said that SDIS uses ontologies, semantic data exchange and harmonisation techniques to integrate data across internal and CRO systems.

This is combined with specialised parametric meta-data extraction, indexing and search technology to deliver new scientific insights across studies.

Additionally, SDIS can be used for contributing study data in standardised formats to alliance partners and collaborative safety data sharing consortia such as IMI.

PointCross stated that in-house processes are provided for the selection of study data to be shared from the internal inventory using simple search and redaction facilities to preserve confidentiality.